O Shaughnessy Asset Management LLC Has $4.74 Million Stock Holdings in GSK plc (NYSE:GSK)

O Shaughnessy Asset Management LLC reduced its position in shares of GSK plc (NYSE:GSK - Free Report) by 19.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 140,276 shares of the pharmaceutical company's stock after selling 32,936 shares during the period. O Shaughnessy Asset Management LLC's holdings in GSK were worth $4,744,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Dorsey & Whitney Trust CO LLC boosted its holdings in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after acquiring an additional 278 shares during the period. Sunbelt Securities Inc. grew its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after buying an additional 302 shares during the last quarter. Rehmann Capital Advisory Group increased its position in GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company's stock worth $232,000 after buying an additional 332 shares during the period. GC Wealth Management RIA LLC lifted its holdings in shares of GSK by 2.6% during the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after buying an additional 353 shares during the last quarter. Finally, Jacobi Capital Management LLC grew its stake in shares of GSK by 3.9% in the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock worth $352,000 after acquiring an additional 389 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

GSK Price Performance

GSK stock traded down $1.69 during trading hours on Monday, hitting $34.85. 7,495,292 shares of the stock were exchanged, compared to its average volume of 4,542,072. The stock has a market capitalization of $72.12 billion, a P/E ratio of 21.92, a P/E/G ratio of 1.12 and a beta of 0.56. The business's 50-day moving average is $37.62 and its two-hundred day moving average is $36.46. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Equities research analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.51%. GSK's payout ratio is currently 98.74%.

Analysts Set New Price Targets

A number of brokerages have weighed in on GSK. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.